The Board of Directors in its meeting held on Saturday, September 30, 2023 has discussed and agreed to provide in principle approval to explore appropriate actions including Merger, Acquisition or other suitable arrangement options for restructuring businesses of Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited to align with long term objectives of the Company. Necessary intimation as required under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be furnished on final approval of Board of Directors of the Company. Board of Directors at its meeting held on 15th March 2024 considered and approved the scheme of Merger by Absorption. The Board at its meeting held on 15.03.2024 Considered and approved the scheme of Merger by Absorption. (As Per BSE Announcement Dated on 16/03/2024) Board of Directors at its meeting held on 18.06.2024 considered and approved the scheme of merger by Absorption (As per BSE Announcement Dated on 18/06/2024) Intimation on receipt of Certified True Copy of order passed by Hon''ble National Company Law Tribunal, Mumbai Bench, (Hon''ble Tribunal) directing the Company to convene a Meeting of the Equity Shareholders and Unsecured Creditors of the Company in the matter of Scheme of Merger by Absorption of Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited with Mangalam Drugs and Organics Limited and their respective shareholders. (As Per BSE Announcement Dated on :09.07.2025) Intimation of CTC of Order copy for C.P. (CAA)210(MB)/2025 NCLT hearing dated 23rd September, 2025 on the matter of merger under Section 230 to 232 of Companies Act, 2013 for final hearing dated 16th December, 2025. (As per BSE Announcement dated on: 15.10.2025)